MedTrace Logo

Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma

NCT07110233 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2026-01-23

No results posted yet for this study

Summary

This is a prospective, single-blinded, single-arm, open-label Phase II trial of trans-arterial radiation segmentectomy using Yttrium-90 glass microspheres (TheraSphere®) for Hepatocellular Carcinoma (HCC) participants with unresectable Barcelona clinic liver cancer (BCLC) stage A disease.

Conditions

Interventions

DEVICE

TheraSphere® Yttrium-90 microspheres

Administered intra-arterially

OTHER

Health Related Quality of Life Questionnaires (HRQOL)

Surveys administered

Sponsors & Collaborators

Principal Investigators

  • Ryan Lokken, MD · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2028-12-31
Completion
2028-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07110233 on ClinicalTrials.gov